Released Aug 10, 2021, before the open
10-Q filed Aug 10, 2021, 41 days after period end · 0001628280-21-016418
Q2 2021 · 10-Q
Revenue$279.00K$279.00K — vs Q2 2020−2.4% vs Q1 2021
Net Income-$23.11M-$23.11M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.63-$0.63 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$23,261,000N/M
Operating Cash Flowderived-$18,483,000N/M
Free Cash Flowderived-$19,692,000N/M
Margins · derived
Operating margin-8337.3%
Net margin-8283.5%
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Revenue | $279.00K | $0.00 |
| Net Income | -$23.11M | -$15.72M |
| EPS Diluted | -$0.63 | -$2.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR